Evidence map›Paper›PMID 38912054›Full record

ArticleInternational journal of chronic obstructive pulmonary disease2024

An Exploratory Study of Physician Decision-Making When Treating Uncontrolled COPD.

Kristin Kahle-Wrobleski, Bonnie K H Bui, Jennifer Friderici, Kristin J Moore, Maureen Carlyle, Noah S Webb, Carolyn K Martin, Wilson D Pace, John M Westfall

Abstract read
In one paragraph

Article in International journal of chronic obstructive pulmonary disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kristin Kahle-WrobleskiUS Value Evidence and Outcomes, GSK, Philadelphia, PA, USA.
Bonnie K H BuiHealth Economics and Outcomes Research, Optum Life Sciences, Eden Prairie, MN, USA.ORCID 0000-0003-1111-5746
Jennifer FridericiHealth Economics and Outcomes Research, Optum Life Sciences, Eden Prairie, MN, USA.ORCID 0000-0002-8773-6154
Kristin J MooreHealth Economics and Outcomes Research, Optum Life Sciences, Eden Prairie, MN, USA.ORCID 0000-0003-2179-6565
Maureen CarlyleHealth Economics and Outcomes Research, Optum Life Sciences, Eden Prairie, MN, USA.ORCID 0009-0005-2792-9332
Noah S WebbHealth Economics and Outcomes Research, Optum Life Sciences, Eden Prairie, MN, USA.ORCID 0009-0009-8379-2050
Carolyn K MartinHealth Economics and Outcomes Research, Optum Life Sciences, Eden Prairie, MN, USA.ORCID 0000-0003-3512-7231
Wilson D PaceDARTNet Institute, Research Department, Aurora, CO, USA.ORCID 0000-0003-1699-5471
John M WestfallDARTNet Institute, Research Department, Aurora, CO, USA.ORCID 0000-0002-1070-0268

Funding

GSK STUDY NUMBER 214995
6 · The paper itself

Abstract

Purpose: Current guidelines recommend triple therapy maintenance inhalers for patients with recurrent exacerbations of chronic obstructive pulmonary disease (COPD); however, these maintenance therapies are underutilized. This study aimed to understand how physicians make COPD treatment decisions, and how combination maintenance therapies are utilized in a real-world setting. Patients and Methods: This exploratory, hypothesis-generating, non-interventional study used a cross-sectional online survey that was administered to a sample of practicing physicians in the United States. The survey included five fictitious vignettes detailing common symptoms experienced by patients with COPD. Survey questions included factors physicians consider in their decisions, and perceived barriers to prescribing treatments. Repeated measures multivariable analyses were conducted to evaluate how likely physicians were to switch to triple therapy versus no change to patient's current maintenance therapy or change to another maintenance therapy. Results: In total, 200 physicians completed the survey. Cost of treatment and patient access to treatment were reported as the most common barriers physicians consider in their prescribing decisions. Physicians were more likely to switch a patient's maintenance inhaler to triple therapy versus no change to maintenance inhaler if they considered the patient's history of new symptoms, insurance status, and clinical guidelines in their decision. Physicians with more experience treating patients with COPD, and those who treat more patients with COPD per week, were more likely to switch to triple therapy versus no change to maintenance inhaler. Conclusion: This study demonstrates the complexity of factors that can influence physicians' decisions when prescribing treatments for patients with COPD, including considerations of treatment cost, patient access and adherence, patient comorbidities, efficacy of current treatment, clinical guidelines, and provider's level of experience treating COPD. Further research may help elucidate the relative importance of the factors influencing physicians' decisions and inform what types of decision-support tools would be most beneficial.

Indexed as

Bronchodilator AgentsClinical Decision-MakingHealth Care SurveysPractice Patterns, Physicians'Pulmonary Disease, Chronic ObstructiveAdministration, InhalationAdultAgedAttitude of Health PersonnelCross-Sectional StudiesDrug CostsDrug Therapy, CombinationFemaleHealth Knowledge, Attitudes, PracticeHealth Services AccessibilityHumansBronchodilator Agentsmaintenance therapypatient vignettepharmacotherapyphysician surveyreal worldtriple therapy

Identifiers

PMID38912054
PMCPMC11193463

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.